Investments and Fair Value Measurements - Schedule of Changes to the Contingent liability (Details) $ in Thousands |
3 Months Ended |
|---|---|
|
Mar. 31, 2025
USD ($)
| |
| Development and Collaboration Agreement | |
| Beginning balance | $ 30,334 |
| Ending balance | 30,977 |
| Ampreloxetine Royalty Rights | |
| Development and Collaboration Agreement | |
| Beginning balance | 30,334 |
| Non-cash interest expense accretion | 643 |
| Ending balance | $ 30,977 |